Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Risk factors for progressive kidney impairment among patients with polycythemia vera (PV) are recapitulated and treatable in mouse models of PV

Brandi Reeves, Marcelo Szymanski de Toledo, Fatima Trebak et al. Nov 03, 2025 pp. 605-605 10.1182/blood-2025-605

Abstract Background: PV is characterized by clonal hematopoiesis, thrombotic events, and potential progression to myelofibrosis (MF). The pr...

Impact of chemotherapy on survival in patients aged 75 years and older with Acute Myeloid Leukemia: A contemporary population-based analysis (2000–2022) from a national database

Noor Khalid, Sarah Makhani, Mohammad Hussain et al. Nov 03, 2025 pp. 4609-4609 10.1182/blood-2025-4609

Abstract Background: Over the years, survival with chemotherapy has improved in older patients with acute myeloid leukemia (AML), but data r...

DARS mediated M2 polarization of tumor associated macrophages drives MPN progression

Hao Xiong, Hanlu Zhang, Ting Niu et al. Nov 03, 2025 pp. 5006-5006 10.1182/blood-2025-5006

Abstract Chronic myeloproliferative neoplasms (MPNs) without the Philadelphia chromosome are clonal diseases of the bone marrow originating...

Impact of treatments with food restrictions on adherence and quality of life aspects among CML patients

Heather Lapidus Glassner, Dan Douer, Emily Lee et al. Nov 03, 2025 pp. 2833-2833 10.1182/blood-2025-2833

Abstract Background In chronic myeloid leukemia (CML), Tasigna (nilotinib) and Scemblix (asciminib) are two current tyrosine kinase inhibito...

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Corbin Wright, Karun Neupane, Junmin Whiting et al. Nov 03, 2025 pp. 5833-5833 10.1182/blood-2025-5833

Abstract Introduction: Elranatamab (Elra) is a BCMA-CD3 bispecific antibody (BsAb) approved for the treatment of relapsed and refractory mul...

Long-term follow-up for newly diagnosed BCR::ABL1 negative B cell acute lymphoblastic leukemia from China: 10-year outcome of RJ-ALL 2014 protocol

Jiayi Ren, Li-Jun Peng, Weiyang Liu et al. Nov 03, 2025 pp. 3333-3333 10.1182/blood-2025-3333

Abstract Introduction Pediatric inspired chemotherapy has been successfully applied in adult acute lymphoblastic leukemia (ALL). Short-term e...

DNA-proximal MYB phosphorylation is required for oncogenic transcription in acute myeloid leukemia

Shuyuan Cheng, Katarzyna Kulej, Christopher Booth et al. Nov 03, 2025 pp. 3239-3239 10.1182/blood-2025-3239

Abstract Dysregulation of gene expression is an essential feature of most human cancers, including acute myeloid leukemia (AML). Despite dis...

Dichotomy of TP53 mutant AML MRD microenvironment: Spatially segregated immunosuppressive mechanisms and niche-specific structural support

Hideaki Mizuno, Yuki Nishida, Edward Ayoub et al. Nov 03, 2025 pp. 6714-6714 10.1182/blood-2025-6714

Abstract Despite recent advances in the treatment of acute myeloid leukemia (AML), most patients with AML relapse and succumb to the disease...

Unraveling the distinct biology of ATLL: Clinical and genetic divergence from other peripheral T-cell lymphomas

Camila Amado Rottier, Gabriel De la Cruz Ku, Bryan Valcarcel et al. Nov 03, 2025 pp. 7076-7076 10.1182/blood-2025-7076

Abstract Background: Adult T-cell leukemia/lymphoma (ATLL) is a distinct entity of peripheral T-cell lymphoma (PTCL) associated with chronic...

Primary central nervous system lymphoma reveals a pro-tumoral brain-specific myeloid landscape.

Subhashini Joshi, María Revuelta, Nahuel Zamponi et al. Nov 03, 2025 pp. 145-145 10.1182/blood-2025-145

Abstract Background: Primary Central Nervous System Lymphoma (PCNSL) ranks among the most aggressive MCD-ABC-DLBCLs driven by MYD88L265P and...

Detection of NPM1 mutation in Acute Myeloid Leukemia by multiple droplet digital PCR and its clinical application value

Keyi Chen, Xinhai Deng, Yixuan Li et al. Nov 03, 2025 pp. 2571-2571 10.1182/blood-2025-2571

Abstract Multiple droplet digital PCR detection of measurable residual disease in NPM1 mutation in acute myeloid leukemia Objective The NPM1...

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Verena Passerini, Vindi Jurinovic, Joshua Tobin et al. Nov 03, 2025 pp. 52-52 10.1182/blood-2025-52

Abstract Background: Follicular lymphoma (FL) remains a clinical challenge due to its relapsing course and difficulty in tailoring therapies...

Economic and clinical impact of emicizumab in people with moderate and severe Hemophilia A in the US

Janet Lee, Fadoua El Moustaid, Lucy Lee Nov 03, 2025 pp. 2610-2610 10.1182/blood-2025-2610

Abstract Introduction: Emicizumab is a recombinant, humanized, bispecific, monoclonal antibody that has become the standard of care in hemop...

Inhibition of PRMT5 with JNJ-64619178 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptosis

Fen Zhu, Jing Wang, Christine Ryan et al. Nov 03, 2025 pp. 5076-5076 10.1182/blood-2025-5076

Abstract Introduction: Protein arginine methyltransferase 5 (PRMT5), a type II arginine methyltransferase, is overexpressed in several aggre...

Cost-effectiveness of heparin-induced thrombocytopenia (HIT) diagnostic strategies: Rapid PF4/heparin versus ELISA-based antibody testing strategies in the care of hospitalized people with suspected HIT

Cecily Allen, Satoko Ito, Adam Cuker et al. Nov 03, 2025 pp. 1072-1072 10.1182/blood-2025-1072

Abstract INTRODUCTION Patients with elevated 4Ts scores for suspected heparin-induced thrombocytopenia (HIT) require imm...

Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma

Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia et al. Nov 03, 2025 pp. 5493-5493 10.1182/blood-2025-5493

Abstract Background: CD19-directed Chimeric Antigen Receptor T-cell therapy (CD19-CAR) is highly effective in recurrent CNS lymphomas (CNSL)...

Idiopathic neutropenia after clonal and antigenic exclusion: A progesterone-dependent subtype

Mark Orland, Carlos Bravo-Perez, Olisaemeka Ogbue et al. Nov 03, 2025 pp. 2995-2995 10.1182/blood-2025-2995

Abstract Chronic idiopathic neutropenia (CIN) is characterized by a persistently reduced absolute neutrophil count, typically <1.5×10...

Autoimmune hemolytic anemia (AIHA) associated with human immunodeficiency virus (HIV) infection: Two challenging cases

Charlotte Nawor, Noah Mehr, Mai H.S. Mohammad et al. Nov 03, 2025 pp. 6441-6441 10.1182/blood-2025-6441

Abstract Background: Patients with HIV often develop hematologic complications. While anemia is multifactorial, elevated direct antiglobulin...

Balancing risk and benefit: Fluoroquinolone prophylaxis in hyper-CVAD for acute lymphoblastic leukemia in a high fluoroquinolone-resistance setting

Rafael Valdez, Maria Fernanda Gonzalez Lara, Mariem Pulido et al. Nov 03, 2025 pp. 5100-5100 10.1182/blood-2025-5100

Abstract Background: Infectious complications are the leading cause of non-relapse mortality in adults with acute lymphoblastic leukemia (AL...

Blood group o and a lower endogenous thrombin potential are associated with increased risk for future bleeding after hemostatic challenges in bleeding disorder of unknown cause

Tim Dreier, Dino Mehic, Justin Oosterlee et al. Nov 03, 2025 pp. 1300-1300 10.1182/blood-2025-1300

Abstract Background. Bleeding disorder of unknown cause (BDUC) is diagnosed in patients who present with clinically significant bleeding sym...

Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation

Lijing Mao, Rongxia Wei, Yuanfeng Zhang et al. Nov 03, 2025 pp. 7737-7737 10.1182/blood-2025-7737

Abstract Background In recent years, growing evidence has demonstrated the potential of anti-thymocyte globulin (ATG) combined with post-tra...

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Inhye Ahn, Ricardo Parrondo, Meghan Thompson et al. Nov 03, 2025 pp. 85-85 10.1182/blood-2025-85

Abstract Introduction: BTK inhibitors are effective treatments for CLL/SLL; however, treatment intolerance and resistance to BTK inhibitors...

Development of a prediction model for maternal pregnancy complications in sickle cell disease

Aaron Cheng, Phyllis Gimotty, David Margolis et al. Nov 03, 2025 pp. 1091-1091 10.1182/blood-2025-1091

Abstract Introduction Pregnant individuals with sickle cell disease (SCD) face dramatically increased maternal risks, with prior work showin...

Concurrent clonality of multiple hematopoietic lineages: Implications for pathogenesis and management of cytopenia

Carlos Bravo-Perez, Carmelo Gurnari, Aashray Mandala et al. Nov 03, 2025 pp. 1391-1391 10.1182/blood-2025-1391

Abstract Blood cells with clonal abnormalities linked with neoplasia have been observed in not only otherwise healthy individuals, but also...

Comorbid COPD as a major independent predictor of post-discharge morbidity in adults hospitalized for sickle cell acute chest syndrome: A national propensity-matched analysis

Mariana Marrero Castillo, Benedict Amalraj, Anil Ananthaneni Nov 03, 2025 pp. 180-180 10.1182/blood-2025-180

Abstract Introduction Patients with sickle cell disease (SCD) experience a state of endothelial dysfunction and hypercoagulability, which el...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page